id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-N-1661-0002,FDA,FDA-2023-N-1661,"Agency Information Collection Activities; Proposals, Submissions, and Approvals",Notice,Notice of Approval,2023-12-22T05:00:00Z,2023,12,,,2024-01-08T13:20:18Z,2023-28290,0,0,0900006486351611
FDA-2023-N-1661-0001,FDA,FDA-2023-N-1661,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Expanded Access to Investigational Drugs for Treatment Use,Notice,30 Day Proposed Information Collection,2023-05-10T04:00:00Z,2023,5,2023-05-10T04:00:00Z,2023-06-10T03:59:59Z,2023-07-17T19:52:50Z,2023-09982,0,0,09000064859ed40b